ResearchVEGF
Genentech Biooncology
multimedia callout footer

References

  1. Hicklin DJ, Ellis LM. J Clin Oncol. 2005;23:1011-1027.
  2. Baka S, Clamp AR, Jayson GC. Expert Opin Ther Targets. 2006;10:867-876.
  3. Presta LG, Chen H, O'Connor SJ, et al. Cancer Res. 1997;57:4593-4599.
  4. Jain RK, Duda DG, Clark JW, Loeffler JS. Nat Clin Pract Oncol. 2006;3:24-40.
  5. Morabito A, De Maio E, Di Maio M, et al. Oncologist. 2006;11:753-764.
  6. Kerbel RS. Science. 2006;312:1171-1175.
  7. Willett CG, Boucher Y, di Tomaso E, et al. Nat Med. 2004;10:145-147.
  8. Borgström P, Hillan KJ, Sriramarao P, Ferrara N. Cancer Res. 1996;56:4032-4039.
  9. Borgström P, Bourdon MA, Hillan KJ, et al. Prostate. 1998;35:1-10.
  10. Yuan F, Chen YI, Dellian M, et al. Proc Natl Acad Sci USA. 1996;93:14765-14770.
  11. Lee CG, Heijn M, di Tomaso E, et al. Cancer Res. 2000;60:5565-5570.
  12. Inai T, Mancuso M, Hashizume H, et al Am J Pathol. 2004;165:35-52.
  13. Tong RT, Boucher Y, Kozin SV, et al. Cancer Res. 2004;64:3731-3736.
  14. Jain RK. Nat Med. 2001;7:987-989.
  15. Jain RK. Science. 2005;307:58-62.
  16. Warren RS, Yuan H, Matli MR, et al. J Clin Invest. 1995;95:1789-1797.
  17. Garcia-Albeniz X. Targ Oncol. 2007;2:241-252.
  18. Gerber HP, Ferrara N. Cancer Res. 2005;65:671-680.
  19. Folkman J. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. Vol 2. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:2865-2882.
  20. Sweeney CJ, Miller KD, Sledge GW. Trends Mol Med. 2003;9:24-29.
  21. Herbst RS. Expert Opin Emerging Drugs. 2006;11:635-650.
Next section

The need for continuous VEGF inhibition